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TNF-αS6K (ribosomal S6 kinase p70, p70S6K) activation requires phosphorylation at two stages. The ﬁrst phos-
phorylation is independent of insulin stimulation and mediated by an unknown kinase. The second phos-
phorylation is mediated by mTOR in insulin dependent manner. In this study, we identiﬁed JNK1 (c-Jun
N-terminal kinase 1) as a kinase in the ﬁrst phosphorylation. S6K protein was phosphorylated by JNK1 at
S411 and S424 in the carboxyl terminal autoinhibitory domain. The phosphorylation was observed in kinase
assay with puriﬁed S6K as a substrate, and in cells after JNK1 activation by TNF-α or MEKK1 expression. The
phosphorylation was detected in JNK2 null cells, but not in JNK1 null cells after TNF-α treatment. When JNK1
activation was inhibited by MKK7 knockdown, the phosphorylation was blocked in cells. The phosphoryla-
tion led to S6K protein degradation in NF-κB deﬁcient cells. The degradation was blocked by inhibition of
proteasome activity with MG132. In wide type cells, the phosphorylation did not promote S6K degradation
when IKK2 (IKKβ, IκB kinase beta) was activated. Instead, the phosphorylation allowed S6K activation by
mTOR, which stabilizes S6K protein. In IKK2 null cells or cells treated by IKK2 inhibitor, the phosphorylation
led to S6K degradation. These data suggest that S6K is phosphorylated by JNK1 and the phosphorylation
makes S6K protein unstable in the absence of IKK2 activation. This study provides a mechanism for regulation
of S6K protein stability.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ribosomal S6 kinase p70 (p70S6K, S6K) is a member of the AGC
family of serine/threonine protein kinases. It mediates signals of insu-
lin, growth factors, mitogens, nutrients and stresses in the regulation
of cell growth and energy metabolism [1]. S6K is required for protein
synthesis in cells and is involved in the negative feedback regulation
of insulin signaling pathway. In obesity, S6K is activated by several
risk factors for type 2 diabetes, such as hyperinsulinemia, inﬂamma-
tion, free fatty acid and branch chain amino acids [1,2]. The activation
contributes to the pathogenesis of type 2 diabetes by induction of in-
sulin resistance. Recent studies suggest that S6K phosphorylates insu-
lin receptor substrate 1 (IRS-1) at multiple serine residues [3–7], by
which S6K inhibits insulin signaling at the post receptor level [7]. In
vivo, S6K knockout protects mice from obesity-induced insulin resis-
tance [8]. In an early study, we reported that S6K was activated by
pro-inﬂammatory cytokine TNF-α in adipocytes, and the activation
was dependent on IKK2 (IKKβ) activity [7]. In the model, S6K medi-
ates IKK2 activity in the inhibition of insulin action. IKK2 regulates
S6K through activation of mTOR, an upstream kinase of S6K in the
classic insulin signaling pathway [9]. In another study, we observed
that in NF-κB p50-KO (knockout) mice, TNF-α was elevated in thel rights reserved.blood circulation without induction of insulin resistance [10]. In mech-
anism, a low level of S6K protein in the liver of p50-KO mice was re-
sponsible for the disassociation of TNF-α and insulin resistance. The
study suggests that S6K activity is required for inﬂammation-induced
insulin resistance. However, the mechanism of S6K reduction was not
known in p50-KO mice. We addressed this issue by investigating the
mechanism of S6K protein stability in the current study.
The activity and subcellular location of S6K are controlled by phos-
phorylation and dephosphorylation [11–13]. Several serine kinases
have been reported to phosphorylate S6K in the process of S6K activa-
tion. The ﬁrst phosphorylation occurs at the C-terminal domain
(S411, S418, T421, S424 and S429) [14]. The phosphorylation releases
the catalytic domain from the inhibition of C-terminal domain in S6K
protein. Those kinases of the ﬁrst phosphorylation step include ERK
(T421/S424) [15], P38 [2], and CDC2 (S411) [16]. It is not known if
JNK1 plays a role in the ﬁrst step phosphorylation. JNK1 is a member
of MAPK (mitogen activated protein kinase) pathway, which includes
ERK and P38. The second phosphorylation occurs on Thr389, which is
catalyzed by mammalian target of rapamycin (mTOR) [17]. Thr389
phosphorylation promotes docking of phosphatidyl-inositide depen-
dent kinase 1 (PDK1), which phosphorylates S6K at T229. Phosphor-
ylation of T389 and T229 results in full activation of S6K [18]. S6K
enzyme activity is inactivated by dephosphorylation that involves
phosphatases such as PP2A and PP1 [19]. In addition to the phosphor-
ylation, S6K activity is regulated by ubiquitination that is catalyzed by
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ubiquitination-mediated regulation of S6K remain to be established
in the pathogenesis of type 2 diabetes. In this study, we found that
the ubiquitination contributes to S6K protein degradation in p50-KO
mice, which protects p50-KO mice from insulin resistance.
We investigated the mechanism of S6K degradation in response to
TNF-α. Our data suggests that JNK1 directly phosphorylates S6K1 at the
c-terminus autoinhibitory domain to facilitate S6K activation. IKK2 con-
tributes to S6K activation by induction ofmTORactivation. In the liver of
p50-KOmice, IKK2 activity was reduced and JNK1 activitywas elevated.
This unique condition led to S6K hyperphosphorylation and protein
degradation after ubiquitination.
2. Material and methods
2.1. Animals
Male p50-KO mice (Stock Number: 002849) and the control mice
(Stock Number: 100903) were purchased from the Jackson Laborato-
ry (Bar Harbor, ME). All of the mice were housed in the animal facility
at the Pennington Biomedical Research Center with a 12:12-h light–
dark cycle and constant temperature (22–24 °C). The mice had free
access towater and chowor high fat diet. All procedureswere performed
in accordance with the National Institutes of Health guidelines for the
care and use of animals and were approved by the Institutional Animal
Care and Use Committee (IACUC) at the institute. The mice were
ear-punched for identiﬁcation and were group housed at four per cage.
2.2. Cells and reagents
Human embryonic kidney (HEK) 293 cells (CRL-1573) were pur-
chased from the American Type Culture Collection (ATCC). Mouse em-
bryonic ﬁbroblast (MEF) cells including IKK2-KO (IKK2−/−), p65-KO,
p50-KO were described elsewhere [10,22]. p65-KO-siMKK7 stable cell
linewas established by transfecting cells with a siMKK7 expression plas-
mid. All cells were maintained in Dulbecco's Modiﬁed Eagle's culture
medium supplemented with 10% fetal calf serum from Sigma (St. Louis,
MO 63103). Antibodies speciﬁc to p70S6K phosphor-S424 (#9204) and
phosphor-Thr389 (#9205), phosphor-IKK (Ser180/Ser181, #2681)
were obtained from Cell Signaling (Beverly, MA). Antibodies to JNK
(sc-7345), p50 (sc-33022), p38 (sc-728), HA (sc-7392), IκBα (sc-371),
phosphor-JNK (sc-6254) and pc-JUN (sc-822) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to S6K (P70S6K)
(ab9366), β-Actin (ab6276) were from Abcam (Cambridge, UK). An an-
tibody to IKKβ (05-535) was from Upstate Biotechnology (Lake Placid,
NY 12946). Rapamycin (A-275) and SP600125 (EI-305) were acquired
from Biomol (Plymouth Meeting, PA). 15-Deoxyprostaglandin J2
(15dPGJ2, 538927), PD98059 (513000), and SB203580 (203580)
were purchased from Calbiochem (San Diego, CA). TNF-α (T6674),
MG132, and anisomycin were obtained from Sigma. Recombinant IKK2
(IKKβ), JNK and p38 were obtained from Upstate Biotechnology.
2.3. Plasmids and transfection
Plasmid forHA-S6K1 (8984)was obtained fromAddgene (Cambridge,
MA) [23]. Expression vector for ﬂag-tagged ubiquitin was constructed
using pcDNA3 expression vector. Expression vectors for HA-S6KΔC and
HA-S6K (S5A) were constructed using vector pRK7. The wild type (WT)
and mutant S6K proteins were expressed in HEK293 or MEF cells
by transient transfection using Lipofectamine. The bacterial expres-
sion vectors for GST-S6K WT, GST-S6K (S411A), GST-S6K (S418A),
GST-S6K (S421A), GST-S6K (S424A), GST-S6K (S429A), GST-S6K
(S411A+424A), GST-S6KΔC and GST-S6K(S5A) were constructed
in PGEX-4T-2 vector. Point mutation and GST-S6K protein prepara-
tion were made using protocols as described elsewhere [22].2.4. Western blot
The whole cell lysate was prepared and the Western blot was
conducted according to methods described elsewhere [7].
2.5. Kinase assay
The kinase assaywas conducted according tomethods reported earli-
er [7]. Brieﬂy, puriﬁed GST-S6K proteinwas diluted in kinase assay buffer
(20 mMHEPES, pH 7.6, 20 mMMgCl2, 20 mMglycerophosphate, 1 mM
dithiothreitol, 10 μM ATP, 1 mM EDTA, 1 mM sodium orthovanadate,
0.4 mM phenylmethylsulfonyl ﬂuoride, 20 mM creatine phosphate).
The kinase assay was conducted at 37 °C for 30 min in 20 μl of kinase
assay buffer containing 5 μCi of γ-
32
P ATP and 2 μl of kinase, such as
JNK, IKK2 and p38. The recombinant kinases were purchased from Up-
state Technology. The phosphorylated S6K was resolved in SDS-PAGE
and visualized by autoradiography. In non-radioactive kinase assays, the
results were determined in immunoblot with phosphor-S6K antibodies.
2.6. Immunoprecipitation (IP)
Immunoprecipitation was carried out by using whole cell lysates
(400 μg protein) with 2–4 μg of antibody, and 20 μl of protein A- or
protein G-Sepharose beads (Amersham Biosciences). The cell lysate
was prepared by sonication in the cell lysis buffer. IP was conducted
by incubating the whole cell lysate with antibody for 3–4 h at 4 °C.
The immune complex was washed ﬁve times in cell lysis buffer before
analysis by immunoblotting.
2.7. Serum TNF-α
Serum TNF-α was measured using a multiplex kit (Cat.#
MADPK-71 k-03, Linco Research, Inc. St. Charles, Missouri, USA).
2.8. Quantitative real time RT-PCR
The TaqMan RT-PCR reaction was used to quantify S6k (Rps6kb1)
mRNA in the total RNA extract thatwas preparedwith the Trizol reagent.
Primers for Rps6kb1 (Mm00659517_m1) and Tnf-α (Mm00443258_m1)
were obtained from Applied Biosystems (Foster City, CA). Mouse ribo-
some 18S rRNA_s1 (without intron–exon junction)was used as an inter-
nal control to normalizemRNAexpression. Reactionwas conductedwith
7900 HT Fast real time PCR System (Applied Biosystems, Foster City, CA).
2.9. Statistical analysis
All experiments were repeated independently at least three times
with consistent results. Student's t-test or one-way ANOVA was used
as appropriate in statistical analysis of the data. P b 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. S6K protein level is decreased in p50-KO mice
In our previous study, a reduction in S6K protein was observed in
the liver of p50-KO mice, and the reduction contributed to the disas-
sociation of inﬂammation and insulin resistance in p50-KO mice [10].
The study suggests that S6K protein is a key to understanding the link
between inﬂammation and insulin resistance. In this study, we ex-
plored the mechanism of S6K protein reduction. First, we examined
S6K protein in all of insulin sensitive tissues including liver, adipose
tissue, and skeletal muscle of p50-KO mice. S6K protein level was dra-
matically decreased in liver and fat, butmodestly reduced in themuscle
of p50-KO mice (Fig. 1A). Then, S6K mRNA was determined in these
tissues to understand the mechanism of S6K reduction (Fig. 1B). The
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Fig. 1. S6K and TNF-α level in p50-KOmice. (A) S6K protein level in tissues. S6K protein was examined in the white adipose tissue (WAT), liver, and muscle of WT and p50-KO mice.
(B) S6K mRNA level was determined by qRT-PCR in the liver, muscle and WAT. (C) TNF-α in p50-KO mice. TNF-α protein was determined in the serum by ELISA. TNF-αmRNA was
determined in the liver, muscle and WAT with qRT-PCR. (D) JNK and IKKβ in liver. Liver tissues of p50-KO mice were examined for JNK, IKK2 and NF-κB p65 and p50. The exper-
iments were conducted 3 times with consistent results and the representative blots are presented. In the bar ﬁgure, each data point represents mean ± SEM (n = 6). *P b 0.05 over
control.
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mRNA expression.
The relationship of protein and mRNA suggests that the S6K pro-
tein reduction may occur at the post-translational level, not at the
transcriptional level. This possibility led us to focus on S6K protein
degradation. In search of factors that may contribute to S6K degrada-
tion, we focused on TNF-α that is able to induce S6K activation [7].
TNF-α was examined in the plasma and an elevation was found in
p50-KO mice (Fig. 1C). Expression of TNF-α mRNA was elevated in
all tissues examined (Fig. 1C). The data suggests that TNF-α elevation
is associated with S6K reduction in p50-KO mice. TNF-α signal is me-
diated by JNK1 and IKK2. Phosphorylation of JNK1 and IKK2 was ex-
amined in the liver tissues in a Western blot. The data showed that
JNK1 activity was enhanced as indicated by its phosphorylation status
(Fig. 1D). IKK2 activity was reduced from the low phosphorylation
status (Fig. 1D). In addition, proteins for IKK2 (IKKβ) and NF-κB p65
subunit were both reduced in p50-KO tissue (Fig. 1D), suggesting a
defect in the IKK2/NF-κB signaling pathway. In wild type cells, JNK1
and IKK2 are both activated by TNF-α. The enhanced JNK1 activity and
reduced IKK2 activity suggest that the two pathways were disbalanced
in the liver of p50-KO mice. NF-κB p50 subunit was absent in the tissue
conﬁrming the complete knockout of p50 activity in the mice (Fig. 1D).3.2. Identiﬁcation of S6K as a new target of JNK1
The data suggests that an increase in JNK1 activity is associated
with the reduction in S6K protein in p50-KO mice. We searched the
literature for their relationship and did not ﬁnd any information about
it. Protein degradation after phosphorylation is a common pathway
for clearance of a signaling protein in the cytosol. This pathway may
play a role in the S6K reduction. If this is the case, S6K is likely phosphor-
ylated by JNK1. To test this possibility, we examined amino acid se-
quence of S6K protein for JNK1-sensitive domains. We found ﬁve S6K
motifs (S411, S418, T421, S424, S429) as potential candidates of JNK tar-
gets (Fig. 2A). In the analysis, the authentic JNK1 target in c-JUN protein
was used as a template (Fig. 2A). To test this possibility, we prepared a
full-length recombinant S6K protein using the bacterial GST-S6K ex-
pression system for JNK1 kinase assay. S6K protein was phosphorylated
by JNK1 in the assay as indicated by enhanced radiolabeling of S6K pro-
tein (Fig. 2B). The phosphorylation was not observed in the presence of
p38. In the positive controls, JNK1 phosphorylated the classic substrate
c-JUN, and p38 phosphorylated its standard substrate MBP (Fig. 2B).
The relationship of IKK2 and S6K was determined too in the kinase
assay. We found IKK2 phosphorylated the classic substrate IκBα, but
not S6K (Fig. 2C). The data suggests that JNK1, but not p38 and IKK2,
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Fig. 2. S6K phosphorylation by JNK1 in kinase assay. (A) JNK1 target sequences in S6K. Amino acid sequence in c-JUN was used as a consensus sequence in the S6K analysis. Five
candidates for JNK-sensitive residues are shown in red font in the c-terminal of S6K. (B) JNK1 kinase assay. The kinase assay was conducted with puriﬁed JNK1 (kinase) and
GST-S6K1 (substrate). The phosphorylation was tracked with radioactivity of
32
P. (C) IKK2 kinase assay. Puriﬁed IKK2 and S6K1 were used with
32
P. IκBα was an authentic IKK2
substrate. (D) Phosphorylation detected with antibody. S424 phosphorylation in S6K was investigated with phosphor-speciﬁc antibody to pS6K(S424) after the kinase assay. In
the negative control, IKK2 and p38 were used in the kinase assay. The phosphor-speciﬁc antibody to pT389 was used in control. (E) Mutation analysis of S6K. Mutant proteins
were tested in the JNK1 kinase assay and relative strength of
32
P signal was quantiﬁed (n = 3). The experiments were repeated three times with consistent results and represen-
tative blots are presented in this ﬁgure. *P b 0.05, **P b 0.001 over control.
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relationship for JNK1/S6K.
The phosphor–serine residues in S6Kproteinwere investigatedwith
phosphor-speciﬁc antibodies and mutation analysis. S424 is one of ﬁve
Ser/Thr-Pro sites in S6K, and an antibody to pS6K(S424) is commercial-
ly available. S6K phosphorylationwas examined in aWestern blot using
the antibody. The result suggests that S424 was phosphorylated by
JNK1 (Fig. 2C). In the test, kinases of IKK2 and p38 were included in
the negative control. A weak pS6K(S424) signal was observed in the
presence of IKK2 or p38 (Fig. 2C). However, the signal is much weaker
relative to that induced by JNK1, suggesting a weak background noise
of the phospho-antibody. In the negative control, phosphorylation of
Thr389 (mTOR target) was examined and it was not changed by any
of the kinases. The data suggest that JNK1 phosphorylates S424 in the
S6K c-terminal.
To test JNK1 effect on other S/T-P sites of S6K,we usedmutant S6K in
the radioactive kinase assay. The mutation was made by c-terminal
truncation and point mutation. In S6KΔC, the c-terminal was deleted
from S6K protein. In S6KS5A, the ﬁve serine/threonine residues in the
c-terminal were all replaced by alanine (A). Mutation in either way
blocked S6K phosphorylation by JNK1 (Fig. 2E), suggesting that JNK1
targets are exclusively located at the c-terminal (Fig. 2E). To identify
the exact target serine residues, we conducted extensive pointmutation
at the c-terminal by replacing each S/T residue with alanine individual-
ly. Themutantswere tested in the kinase assay (Fig. 2E).Mutation of ei-
ther S411 (S411A) or S424 (S424A) individually reduced, but did not
abolish the JNK1-mediated phosphorylation (Fig. 2E). Mutation of the
two residues together (S411A+S424A) completely blocked the phos-
phorylation (Fig. 2E). Mutation of other residues (S418, S421 and S429)
did not reduce the phosphorylation. These data suggest that in the ﬁve
residues of c-terminal, both S411 and S424 are JNK targets.
3.3. JNK1 is involved in TNF-α-mediated S6K activation
If JNK1 phosphorylates S6K in a physiological condition, the two
proteins should interact with each other in cells when JNK1 is activated.To test this possibility, we performed immunoprecipitation (IP) using
HA-tagged S6K protein (HA-S6K) that allows isolation of recombinant
S6K with HA antibody. HA-S6K was expressed in HEK293 cells, and
then puriﬁed in IP from the cells, which were treated with TNF-α to ac-
tivate JNK1. In the IP product of S6K, a strong JNK1 signal was detected
(Fig. 3A). In the IP product of JNK1, a strong S6K signal was found
(Fig. 3A). The results suggest that S6K was associated with JNK1 in the
cells. The status of S6K phosphorylation was examined in the same
cell system. An increase in pS6K(S424) signal was observed in the
cells after TNF-treatment for 30 min (Fig. 3B). The phosphorylation
was inhibited by JNK inhibitor (SP), but not by mTOR inhibitor (Rap),
p38 inhibitor (SB) or ERK inhibitor (PD) (Fig. 3B). T389phosphorylation
(pS6K389) was increased in the cells by TNF-α, and the signal was dra-
matically inhibited by JNK inhibitor (SP) and mTOR inhibitor (Rap)
(Fig. 3B), suggesting that the JNK-mediated phosphorylation is likely re-
quired for Thr389 phosphorylation by mTOR. These data suggest that
S424 phosphorylation may be required for S6K activation by TNF-α.
S6K phosphorylation in response to mitogen was proposed to be re-
quired for subsequent phosphorylation by mTOR in Avruch's model
[18]. These data suggest that JNKmay prime S6K through phosphoryla-
tion of S424 and other S/T residues at the c-terminal.
3.4. S6K degradation in NF-κB deﬁcient cell lines
Above data suggests that NF-κB activity may be required for stabili-
zation and activation of S6K. To test this possibility, we examined S6K
protein in MEF cells with modiﬁed NF-κB activity. In wild type (WT)
MEFs, the S6K reduction was not observed in response to TNF-α chal-
lenge although S6K (S424) phosphorylation was enhanced (Fig. 4A).
In p50-KO MEFs, S6K was reduced at 30 min and S6K disappearance
was observed at 2 h after the TNF-treatment (Fig. 4B). The reduction
was associated with enhanced JNK1 activity as indicated by persistent
c-JUN phosphorylation. To test the role of IKK2/NF-κB further, S6K
was examined in MEFs, in which the pathway activity is decreased by
knockout of IKK2 or p65 gene. In both cell lines, S6K was reduced by
TNF-α treatment (Fig. 4C and D). The reduction was accompanied by
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Fig. 3. S6K-JNK interaction in cells. (A) Association of S6K and JNK in HEK 293 cells. The cells were transfected with HA-S6K and treated with TNF-α. Immunoprecipitation was
conducted with HA antibody or JNK antibody. The product was blotted for endogenous JNK or HA-S6K in an immunoblot. (B) Inhibition of S424 phosphorylation by JNK inhibitor.
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tion by JNK1. These results suggest that in the absence of IKK2/NF-κB
activity, JNK1 is activated persistently to induce S6K over phosphoryla-
tion, which is suggested by the consistent pS6K(S424) signal in the
presence of S6K protein reduction (Fig. 4C andD). To test the possibility,
we inhibited JNK1 activity in p65-KO MEFs by knocking down MKK7.
MKK7 (also known as JNKK2) is required for TNF-induced JNK activation.
The knockdown attenuated JNK1 activity as indicated by reduction in
c-JUN phosphorylation (Fig. 4E). The JNK1 inhibition blocked S6K(S424)
phosphorylation and S6K protein reduction. The data suggests thatTNF-α (H)     0      
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6K(T389), and pc-JUN. (B) S6K degradation in p50-KO MEF cells. (C) S6K degradation in
K7 knockdown in p65-KO cells. MKK7 was knocked down using siRNA in p65-KO cells.
s are presented in this ﬁgure.
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pathway is required for TNF-α activation of S6K.
3.5. JNK1 activation leads to S6K S424 phosphorylation
To determine the role of JNK1 in the control of S6K phosphorylation
in cells, JNK1 was activated byMEKK1 over-expression or chemical acti-
vator (anisomycin). In transient transfection, over-expression of wild
type JNK1 did not enhance JNK1 activity, and had no effect on phosphor-
ylation of the substrate protein c-JUN (Fig. 5A). In this condition, S424
phosphorylation was not changed in S6K. When JNK1 was activated by
MEKK1 (a potent activator of JNK) in a cotransfection, the phosphoryla-
tion of both c-JUN and S6Kwas enhanced (Fig. 5A). Expression ofMEKK1
alone increased the phosphorylation as well, but at much lower activi-
ties. Activation of JNK1 by the chemical activator (anisomycin) led to
the same effect in S6K phosphorylation (Fig. 5B). In the control, S6K
phosphorylationwas induced by TNF-α in the samemodel, but S6K pro-
tein was not reduced dramatically (Fig. 5B). Activation of IKK2/NF-κB by
TNF-α is likely responsible for the stabilization of S6K. These data suggest
that JNK1 over activation fromgenetic or chemicalmodiﬁcation is able to
induce S6K phosphorylation. The data conﬁrm that S424 phosphoryla-
tion does not induce a dramatic S6K degradation in WT cells.
3.6. S6K in JNK1 deﬁcient cells
JNK1 and JNK2 are two closely related JNK isoforms, but have different
functions. JNK1 is activated by stress responses. JNK2 negatively regulates
JNK1 activation in certain conditions. In this study, we differentiated JNK1
and JNK2 activities in the regulation of S6K protein. The study was
performed in JNK1−/− and JNK2−/− MEF cells. S6K protein was deter-
mined in the cells after TNF-α treatment. In WT MEFs, S6K protein was
not reduced in response to TNF-α (Fig. 6A). In JNK1−/− cells, S6K was
not reducedby the TNF-treatment, and instead, S6Kproteinwasmodestly
elevated (Fig. 6B). The increased S6Kwas associated with a low signal for
pS6K(S424) and c-JUN phosphorylation in JNK1−/− cells (Fig. 6B and C),
in which the phosphorylation was not observed at 2 h (Fig. 6B and C).
In contrast, S6K protein was reduced dramatically in JNK2−/− cells in
response to TNF-α (Fig. 6D). The reduction was associated with a high
JNK activity as shown by c-JUN phosphorylation. The S6K reduction
was blocked by JNK inhibitor (SP) and proteasome inhibitor MG132
(Fig. 6E). The JNK inhibitor was not able to block the degradation
completely in the test. This might be due to enhanced JNK1 activity in
compensation for JNK2 inactivation. In contrast, the reduction was en-
hanced when IKK or mTOR activities were inhibited by IKK inhibitorS6K
pS6K (S424)
pc-JUN
Actin
JNK
A. MEKK1 expression 
- JNK1 JNK1 MEKK
+
MEKK1
Fig. 5. The effects of JNK1 activation on S6K phosphorylation. (A) S6K protein in cells with JN
or in cotransfection with MEKK1 expression vector. S6K protein was determined in the cell ly
response to anisomycin. HEK293 cells were treated with TNF-α (20 ng/ml) or anisomycin
were determined in the whole cell lysates in an immunoblot. The experiments were repea
ﬁgure.(15d) or mTOR inhibitor (Rap) (Fig. 6E). Given that IKK2 enhances
mTOR activity, the data support that mTOR may stabilize S6K protein.
Taken together, the results suggest that JNK1 (not JNK2) activity is re-
quired for S6K degradation. S6K degradation is dependent on proteasome
and S6K protein is stabilized by mTOR.3.7. Regulation of S6K stability by ubiquitination
It is believed that the c-terminal keeps S6K from activation. The
phosphorylation releases S6K from the c-terminal inhibition [2]. How-
ever, it is not known how the c-terminal controls S6K protein stability.
To address this issue, we comparedWT S6K and S6Kmutants in protein
stability. S6KΔC lacks 104 amino acids at the c-terminal. In S6KS5A, the
ﬁve serine/threonine residues (S411, S418, T421, S424, and S429) were
replaced by alanine. TheWT andmutant S6Kwere HA-tagged, and their
protein stability was determined in 293 cells after a transient transfec-
tion. After 48 h in transfection,WT and S6KS5A exhibited the same pro-
tein abundance in the transfected cells (Fig. 7A). However, S6KΔC
protein was dramatically decreased in the system (Fig. 7A).
Protein degradation is often a result of protein modiﬁcation by
ubiquitination. If S6KΔC is degraded, it may be ubiquitinated. To
test this possibility, we examined modiﬁcation of S6KΔC protein by
ubiquitination in this study. Flag-tagged ubiquitin was expressed
withHA-S6KΔC in 293 cells in a cotransfection assay. Protein degradation
was blocked using the proteasomal inhibitorMG132. TheHA-S6KΔC pro-
tein was collected in IP with HA antibody. Ubiquitin was detected in the
isolated HA-S6KΔC protein using the anti-ﬂag antibody in an immuno-
blot (Fig. 7B). The ubiquitination was observed in the basal condition,
and the signal was enhanced by MG132 treatment. The data suggest
that without the c-terminal, S6K protein is subject to ubiquitination
that promotes S6K degradation.
A time course studywas conducted to examine S6KΔC degradation at
1, 3 and 6 h after addition of proteasomal inhibitor MG132 (Fig. 7C). The
study was done in the absence of JNK1 activation to exclude the effect of
phosphorylation. In the test, S6KΔC protein was increased gradually in a
time-dependent manner. In the same condition, WT S6K protein did not
exhibit the increase. The data suggests that the loss of c-terminal makes
S6K protein unstable, suggesting that a change in the c-terminal struc-
ture is important in the control of S6K protein stability.
In the full length protein, the c-terminal is regulated by phosphor-
ylation status. If the phosphorylation is absent, the c-terminal will not
have a structural change and this condition should keep S6K from ac-
tivation. Our data suggests that the condition also prevents S6K from
degradation. To test this effect of phosphorylation, we compared S6KS6K
Actin
pS6K(S424)
pS6K(T389)
pc-JUN
- TNF-α ANI
B.  Active JNK
1
K1 activation. HEK293 cells were transfected with the expression vector for JNK1 alone
sate together with signals of JNK, pc-JUN, and pS6K (S424). (B) S6K phosphorylation in
(ANI) for 30 min to activate JNK. Signals of S6K, pS6K(S424), pS6K(T389) and pc-JUN
ted three times with consistent results and representative blots are presented in this
A. JNK WT B. JNK1 KO
E. InhibitorD. JNK2 KO
C. Phosphorylation 
Fig. 6. S6K was not degraded in JNK1 knockout MEF. The S6K degradation was examined in JNK1−/− and JNK2−/− embryo ﬁbroblast cells. MEF cells were treated with TNF-α after
serum-starvation overnight to induce the protein degradation. S6K protein level was determined in an immunoblot with S6K antibody. Phosphorylated c-JUN (pc-JUN) was a positive
control for JNK activity. (A) S6K in wild type cells. (B) S6K in JNK1 null cells. (C) S6K phosphorylation in wild type and JNK1−/− cells. pS6K (S424) was determined in wild type and
JNK1−/− cells after TNF-treatment for 2 h. (D) S6K degradation in JNK2 KO cells. (E) Inhibition of S6K degradation by inhibiting JNK or proteasome. Before TNF-treatment,
JNK2−/−- cells were pretreated with JNK inhibitor SP600125 (SP, 25 μM), IKK inhibitor 15dPGJ2 (15d, 5 μM), mTOR inhibitor rapamycin (Rap, 200 nM) or proteasomal inhibitor
MG132. The experiments were repeated three times with consistent results and representative blots are presented in this ﬁgure.
1986 J. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 1980–1988and S6KS5A in protein stability in JNK2 null cells, which have an in-
creased JNK1 activity. The two proteins were stably expressed in
JNK2−/−MEFs, respectively, through stable transfection to avoid the in-
ﬂuence of transfection efﬁciency. The protein abundancewas examined
in cells after TNF-α treatment to activate JNK1. A reduction was
observed in WT S6K protein, but not in the mutant S6K (S6KS5A)
(Fig. 7D). The data suggests that the c-terminal phosphorylation is re-
quired for S6K protein degradation.A. Protein
C. MG132
Fig. 7. Deletion of the c-terminal regulatory domains enhances the ubiquitination of S6K. (A
after transfection. (B) Ubiquitination of S6K. HA-S6KΔC was expressed in 293 cells in cotran
tion. HA-S6KΔC was collected by immunoprecipitation with HA antibody 6 h later and the
HA-S6KΔC in HEK293 cells. HEK293 cells were transiently transfected with HA-S6K and HA
times as indicated. The protein amount was determined with the anti-HA antibody. (D) B
and HA-S6KS5A were stably expressed in JNK2−/− cells. S6K degradation was induced TNF
with anti-HA antibody. The experiments were repeated three times with consistent results4. Discussion
S6K protein degradation is a new mechanism in the regulation of
S6K activity. In the classic insulin signaling pathway, S6K is activated
by mTOR at the downstream of PI3K/Akt. The activation involves S6K
phosphorylation at T389 by mTOR, which enhances protein synthesis
through phosphorylation of ribosomal protein S6 by S6K. Recently,
S6K has been reported to mediate nutrient signals in the regulationD. JNK2 KO
B. Ubiquitination
) Expression levels of S6K WT, S6KS5A and S6KΔC were determined in HEK293 in 48 h
sfection with ﬂag-tagged ubiquitin. MG132 (10 μM) was added at 48 h after transfec-
n detected for ubiquitination with ﬂag antibody in an immunoblot. (C) Degradation of
-S6KΔC. The cells were treated with vehicle (DMSO) or MG132 (10 μM) for different
locking S6K degradation by mutation of c-terminal serine/threonine residues. HA-S6K
-α (20 ng/ml) for different times. The protein was quantiﬁed in the whole cell lysates
and representative blots are presented in this ﬁgure.
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acids through mTOR [24,25], and by TNF-α through IKK2 (IKKβ)
[7,9]. In those responses, S6K is shown to phosphorylate IRS-1 in
the inhibition of insulin signaling pathway [6,7]. S6K activation is
controlled by phosphorylation at two stages, one dependent on insu-
lin by mTOR-mediated phosphorylation and one independent of insu-
lin by MAP kinase. There is little information about S6K regulation by
degradation [2]. In the current study, we identiﬁed JNK1 as a kinase in
the insulin-independent phosphorylation of S6K. In addition, we
found that the phosphorylation may lead to S6K protein degradation,
which represents a new mechanism in the regulation of S6K activity.
This mechanism provides an answer to the reduced S6K activity that
was observed in our study of p50-KO mice [26].
We found that JNK1 is a kinase to phosphorylate S6K at S411 and
S424 in the c-terminal autoinhibitory pseudosubstrate domain in
cells. The proline-directed sites of S6K in the c-terminal contain ﬁve
serine/threonine residues (S411, S418, T421, S424 and S429), which
are phosphorylated in response to growth factors and mitogens. The
phosphorylation primes S6K for subsequent phosphorylation by mTOR
[27,28]. The modiﬁcation leads to a conformational change in S6K,
which relieves the inhibitory activity of c-terminal domain [14,29]. Mu-
tation studies suggest that although the modiﬁcation contributes to
S6K1 activation in cells, the phosphorylation is not required for
S6K activation in vitro. Mutation of these serine/threonine sites to al-
anine residues or deletion of 104 amino acids at the c-terminus only
modestly reduces S6K1 activity in vitro. Substitution of the Ser/Thr resi-
dues with phosphor-mimetic residues (D3E) modestly increases S6K
activity [23,30,31]. The phosphorylation occurs in response to mitogen-
responsive kinases [27], the role of JNKwas unclear in the S6K regulation
[2]. Our point mutation data suggest that JNK1 phosphorylates S6K at
S411 and S424 at the c-terminal in cells. Western blot data suggests
that IKK2 and P38 may phosphorylate S6K protein (Fig. 2C). This possi-
bility was tested in the kinase assay using radioactive
32
P-labeled ATP.
The result suggests that IKK2 does not phosphorylate S6K directly. No
P38 activity was observed in the same condition (Fig. 2B). The data sug-
gests that IKK2 and P38 do not directly phosphorylate S6K. TheWestern
blot signal might be non-speciﬁc for IKK2 and P38.
Our data suggests that S6K integrates signals of JNK1 and IKK2 in
the TNF-α signaling pathway. Serine kinases JNK1 and IKK2 are signal-
ing molecules in the TNF-α pathway. In this study, we ﬁnd that they
regulate S6K protein stability and activation. S6K c-terminus was phos-
phorylated by JNK1. In an early study, we reported that TNF-α activated
S6K through IKK2 [7], which induced mTOR activation by inhibition of
TCS1 (tuberous sclerosis 1) [9]. In the current study, our data suggests
that in the presence of IKK2 activity, JNK1-mediated phosphorylation
promotes S6K activation through mTOR activation. In the absence of
IKK2 activity, the phosphorylation leads to S6K degradation in cells.
This conclusion is supported by S6K degradation in IKK2 null cells and
S6K degradation after c-terminus deletion (S6KΔC). These data suggest
that JNK1 and IKK2 have different effects in the regulation of S6K activity
and stability. The mTOR-mediated phosphorylation acts to stabilize the
S6K protein in response to IKK2 activation in the physiological condition.
S6K1 degradation is mediated by ubiquitination and proteasome.
We observed that S6K was ubiquitinated in cells. This observation is
consistent with those in other reports on S6K [20,21]. Our data suggests
that the modiﬁcation may happen in the physiological conditions when
JNK1 is over activated, which induces S6K over phosphorylation at the
c-terminal. The ubiquitination is likely accelerated in the absence of the
c-terminus as indicated by S6K mutant (S6KΔC) that lacks 104 amino
acids at the C-terminal of S6K. S6KΔC exhibited a low protein level
in cells from quick degradation. The protein was ubiquitinated in the
basal condition. The ubiquitination was enhanced in cells in response
to proteasome inhibitor MG132. These data suggest that ubiquitination
leads to S6K degradation.
Our ﬁnding explains the S6K reduction in NF-κB p50-KO mice. In
p50-KO mice, TNF-α is expressed at a high level from enhanced NF-kBactivity in the absence of p50 [26]. The enhanced NF-κB may induce a
negative feedback to reduce IKK2 activity [26]. Lack of IKK2 activity
leads to persistent JNK1 activation in response to TNF-α. IKK2 is known
to inhibit JNK1 activity in general. Current study suggests that in
p50-KO hepatocytes, lack of IKK2 activity leads to S6K degradation
due to JNK1 over activation. Without IKK2 activity, mTOR cannot be
activated to protect S6K in cells treated with TNF-α. The data suggests
that S6K reduction is a result of disbalance between IKK2 and JNK1 in
p50-KO cells.
In summary, our study provides a newmodel for regulation of S6K
activity. In the physiological condition, S6K activation is induced by
TNF-α through activation of JNK1 and IKK2. JNK1 phosphorylates S6K
at the c-terminal (S411 and S424) to induce a conformation change in
the protein, which is independent of insulin activity. In the presence
of IKK2 signal, the structural change promotes S6K1 activation by
mTOR-mediated phosphorylation. In the presence of IKK2 inhibition,
S6K is subject to ubiquitination and degradation after the JNK1-
mediated modiﬁcation. There are two effects by which IKK2 inhibits
S6K degradation: (a) To prevent JNK1 over activation by inhibition
of JNK1. (b) To induce mTOR activation that leads to activation and
stabilization of S6K protein. In conclusion, JNK1 is a serine kinase that
phosphorylates S6K1 at c-terminal that leads to S6K's being either deg-
radation or activation dependent on mTOR activity.
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